secwatch.observer — SEC 8-K summary
======================================

Issuer:     IN8BIO, INC. (INAB)
CIK:        0001740279
Form:       8-K
Filed at:   2024-09-04T23:59:59+00:00
Accession:  0001193125-24-213132
Event type: other_material
Sentiment:  negative
Materiality: 0.80
Item codes: 2.05, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

IN8bio cuts workforce 49%, suspends GBM trial to focus on AML therapy INB-100
-----------------------------------------------------------------------------

- Workforce reduced from 37 to 19 FTEs; exec/board take 11% cash compensation cut.
- One-time severance costs of ~$0.3M expected in Q3 2024.
- INB-100 Phase 1 AML trial shows 100% relapse-free survival at median 18.7 months follow-up; expansion cohort targeting ~25 patients by H1 2025.
- Enrollment suspended in INB-400 Phase 2 GBM trial; IN8bio will monitor existing patients and explore partnerships.
- Company exploring other strategic alternatives to preserve cash.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1740279/000119312524213132/0001193125-24-213132-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1740279/000119312524213132/d855704d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-213132

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer